Liver Cancer Drugs Market Size

Liver Cancer Drugs Market was valued at USD 2.9 billion in 2023 and is estimated to grow at 11.8% CAGR from 2024 to 2032, due to the rising incidence of liver cancer, awareness for early detection, growing research capabilities for potential treatment. The global burden of liver cancer is driven by factors such as increasing rates of hepatitis infections, alcohol consumption and obesity many others. According to the National Center for Biotechnology Information (NCBI), liver cancer is a major global health concern, projected to affect over 1 million people by 2025. Therefore, the growing incidence of liver cancer along with advancement in liver cancer diagnostics anticipate the market growth in the coming years.

Liver cancer drugs are pharmaceutical treatments specifically designed to combat liver cancer, a malignant condition affecting the liver. These drugs include various classes such as targeted therapies, immunotherapies, and chemotherapy agents. The development and use of these drugs aim to inhibit tumor growth, reducing the symptoms, and improving survival rates, of liver cancer patients.